Career Strategy
How to Document Original Contributions for an O-1A Petition When You Are a Regulatory Affairs Professional Whose Work Influences FDA Guidance Documents in 2026
Regulatory affairs professionals whose most significant contributions are embedded in FDA docket comments and guidance development can satisfy the O-1A original contributions criterion — but only with evidence that traces the influence of those submissions on the regulatory framework.
What the original contributions criterion demands from regulatory professionals
The original contributions criterion under 8 C.F.R. § 214.2(o)(3)(ii)(A)(5) requires evidence of original scientific, scholarly, artistic, athletic, or business-related contributions of major significance in the field. For regulatory affairs professionals, this criterion presents a structural challenge: the most consequential work in the field — the submissions, review responses, and advisory inputs that shape FDA guidance documents — is produced in a professional rather than academic context, rarely carries a single author's name on a published article, and is sometimes embedded in regulatory records that are not designed to be cited as scholarly contributions.
Despite these structural differences from academic research, the original contributions criterion is not categorically inaccessible to regulatory affairs professionals. USCIS adjudicators evaluating O-1A petitions apply a functional standard — whether the contribution was original and of major significance in the field — not a form-based standard requiring that the contribution be a journal article or a patent. A regulatory submission that demonstrably shaped a final FDA guidance document, a comment that reframed an agency's analytical approach to a specific regulatory question, or a regulatory strategy framework that became widely adopted in the industry can all satisfy the original contributions criterion when presented with evidence of their actual influence.
The challenge is documentation. Unlike a cited journal article, a regulatory contribution's influence on agency thinking is not automatically recorded in a publicly accessible database. Establishing that a specific submission, comment, or recommendation had major significance in the field requires building an evidentiary record from public agency dockets, guidance document preambles, expert declarations, and industry publications. This section explains what the criterion actually requires, what evidence reliably satisfies it, and how to structure the argument for adjudicators who are unlikely to have prior experience evaluating regulatory affairs careers.
What the regulation requires for non-academic contributors
The regulation at 8 C.F.R. § 214.2(o)(3)(ii)(A)(5) does not require that original contributions take any particular form. USCIS's own Policy Manual clarifies that the contributions must be in the person's field of expertise and must be of major significance — meaning contributions that have had or are likely to have a significant impact on the field beyond the petitioner's immediate workplace or employer. For regulatory affairs professionals, the field is typically defined by the regulatory discipline — drug regulatory affairs, medical device regulatory strategy, combination product submissions — and the impact of a contribution is measured by whether it influenced regulatory outcomes, agency interpretations, or industry practice in that discipline.
Major significance in the regulatory affairs context means something more than successfully executing a routine regulatory submission. An NDA filing, a 510(k) clearance, or a standard BLA submission, however complex, is an expected output of competent regulatory practice — not an original contribution of major significance. The standard is met when a submission, comment, or strategy represented a genuinely novel approach to a regulatory question, influenced how the FDA or another regulatory agency approached a class of submissions beyond the individual case, or established a framework that other practitioners adopted in structuring their own regulatory programs.
The USCIS Policy Manual also notes that the criterion can be satisfied through a combination of evidence that, taken together, establishes a pattern of original contributions — meaning that a regulatory affairs professional who has contributed to multiple guidance documents, published peer-reviewed articles in regulatory science, and served on ICH expert working groups may satisfy the criterion through accumulation even where no single contribution is individually decisive. This totality-of-evidence approach is particularly important for regulatory affairs professionals whose influence is distributed across many submissions and advisory roles rather than concentrated in a single dramatic milestone.
Evidence that routinely satisfies the criterion in regulatory careers
The most direct evidence of original contributions for regulatory affairs professionals is participation in the development of FDA guidance documents through the public comment process on Dockets.gov. When a professional's written comment to an FDA docket can be shown to have influenced the final guidance document — either by tracing specific language changes between the draft and final guidance to the substance of the comment, or through a declaration from an FDA official or industry expert who observed the influence of the submission — this provides concrete evidence of a contribution that affected the field beyond the individual filing. The public comment record and the final guidance document are both publicly available, making the evidentiary chain traceable.
Participation in ICH expert working groups — the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use — provides a particularly strong form of original contributions evidence because ICH guidelines directly shape regulatory requirements across multiple major markets. A professional who served as a named contributor or rapporteur to an ICH working group that produced a harmonized guideline has documentary evidence of a contribution that influenced regulatory practice in the United States, European Union, and Japan simultaneously. ICH working group participation is documented in the guidelines themselves and in the meeting records that ICH publishes, providing an independently verifiable record of the contribution.
Publications in regulatory science journals — including Regulatory Toxicology and Pharmacology, the Journal of Law and the Biosciences, Drug Safety, and the Drug Information Journal — can establish original contributions for regulatory affairs professionals who have published peer-reviewed analyses of regulatory frameworks, submission strategies, or agency decision-making patterns. Articles that introduce a novel analytical framework for evaluating regulatory risk, critique an existing guidance document's scientific basis, or propose a revised approach to a category of submissions satisfy the scholarly publication element while simultaneously demonstrating original thinking in the regulatory domain. These publications are assessed by USCIS as scholarly articles and as contributions evidence simultaneously.
Evidence USCIS regularly discounts from regulatory submissions
Routine regulatory submissions — standard INDs, NDAs filed under established approval pathways, annual reports, and IND safety reports — are not evidence of original contributions regardless of how technically complex they are. These submissions are the expected professional output of regulatory affairs work and are evaluated by USCIS as evidence of competence, not originality. Submitting a complete and well-organized NDA demonstrates that the petitioner knows how to do the job; it does not establish that the petitioner did something that others in the field had not done or could not do, or that the submission influenced the regulatory framework beyond the individual product approval.
Internal regulatory standard operating procedures, CMC strategy documents prepared for a single product, and pre-submission meeting materials that were not incorporated into public guidance are also regularly discounted by USCIS as original contributions evidence. These documents are by their nature proprietary, not publicly accessible, and not evaluable as to their influence on the field beyond the petitioner's employer. Even when an internal SOP represented genuinely innovative thinking about a regulatory problem, the absence of any mechanism by which that innovation influenced practice in the broader field means it cannot satisfy the major significance requirement.
Patent applications listing the petitioner as a co-inventor on drug formulation or manufacturing process patents may support an O-1A petition in some circumstances, but they are weaker original contributions evidence for regulatory affairs professionals than for scientists working primarily in R&D. Patents granted on regulatory strategy, submission structure, or administrative processes are rare and often narrowly scoped. A granted utility patent on a manufacturing process is more persuasive than a pending patent on a regulatory framework concept, and both are more persuasive when accompanied by evidence that the patented method has been independently adopted or licensed.
How to present borderline influence as original contributions
The most common evidentiary challenge for regulatory affairs professionals is documenting the influence of a submission or advisory contribution when the connection between the petitioner's input and the agency's ultimate decision is not directly traceable in the public record. In these situations, the strongest approach is to obtain declarations from experts who observed the submission's influence — former FDA division directors, senior regulatory consultants, or peer practitioners who reviewed both the submission and the final guidance and can attest to the relationship between them. An expert declaration that explains, with specific references to the regulatory record, why a particular submission changed how an agency division approached a class of decisions is substantially more persuasive than a general statement that the petitioner is a recognized leader in the field.
Industry publications and trade press coverage that specifically identifies the petitioner's submission, comment, or regulatory strategy as influential in shaping an FDA outcome also provides supporting evidence of major significance. Articles in RAPS Regulatory Focus, MedTech Intelligence, or the Pink Sheet that describe a submission strategy or public comment as having influenced a final regulatory position are independently generated evidence of field impact — not self-reported by the petitioner or their employer. When the petitioner's work is cited in an industry publication's analysis of why a guidance document changed between its draft and final form, that citation establishes both originality and major significance in a format that USCIS can evaluate.
For regulatory professionals whose influence on FDA guidance is genuine but not yet reflected in any public record — because the guidance is still in development or the comment-response process is ongoing — the most appropriate approach is to focus the original contributions argument on prior contributions where the evidence chain is complete, while documenting the pending contribution as a forward-looking indicator of standing in the field. Filing an O-1A petition while a significant regulatory proceeding is ongoing can be appropriate if the petitioner's existing record already satisfies two or three O-1A criteria; the petition should not depend on a pending contribution that cannot yet be evidenced.
Building and auditing your original contributions file
Building a defensible original contributions file for a regulatory affairs O-1A petition requires working backward from the actual evidence of influence. The most productive starting point is identifying every formal proceeding — FDA docket submissions, ICH working group contributions, public comment letters, guidance development advisory inputs — where the petitioner participated and where a public record of that participation exists. For each item, the practitioner or their counsel should assess whether there is evidence connecting that contribution to a downstream change in the regulatory framework — in a final guidance document, an agency policy shift, an industry adoption pattern, or expert recognition — and whether that evidence can be documented.
Expert letters should be solicited from people who are specifically positioned to evaluate both the originality and the significance of the petitioner's contributions — not simply from senior practitioners who can attest to the petitioner's reputation. The ideal letter writer for a regulatory affairs original contributions argument is someone who has reviewed the specific guidance documents or regulatory proceedings the petitioner contributed to, who is themselves recognized as an expert in that regulatory domain, and who can explain in specific terms why the petitioner's contribution represented something more than skilled execution of standard regulatory practice. Letters that frame the contribution in terms of what changed in the regulatory environment as a result are more persuasive than letters that describe what the contribution was.
A complete original contributions file for a regulatory affairs professional typically includes: the public comment or submission record from Dockets.gov or the relevant agency docket; the final guidance document or policy statement showing the outcome the petitioner's contribution influenced; any ICH working group membership records or acknowledgment in published guidelines; peer-reviewed publications in regulatory science journals; expert declarations from qualified practitioners; and industry press coverage that specifically identifies the petitioner's work as influential. When assembled coherently and introduced through a petition brief that explains the evidentiary chain, this file can satisfy the original contributions criterion even in the absence of traditional academic metrics like citation counts.
What we typically gather for this kind of case
| Document | Where to source | Why it matters |
|---|---|---|
| Peer-reviewed publications | Web of Science / Scopus exports | Anchors original-contributions and authorship criteria |
| Citation analysis | Google Scholar profile + ESI top-1% data | Quantifies major significance in the field |
| Salary benchmark | BLS OEWS for SOC code + locality | Documents high-salary criterion at 90th-percentile or above |
| Critical-role letters | Direct supervisor + program director | Establishes role's importance, not just title |
What we see go wrong, again and again
- 01Treating extraordinary ability as a credentials checklist rather than a story of field-wide impact.
- 02Submitting bibliometric data (h-index, citation counts) without explaining what makes those numbers high relative to peers in the same sub-field.
- 03Relying on letters from collaborators or co-authors rather than independent experts who can speak to influence.
See if you qualify
Lando reviews your background against the O-1 visa criteria and tells you honestly where you stand. Free, no commitment.